Apogee Therapeutics and Sagimet Biosciences offered new details on their IPO plans Monday morning, saying they look to raise $228 million and $66 million in their respective Nasdaq listings, which could take place as early as this week.
The biotechs filed their price ranges with the SEC after last week’s Fourth of July holiday when many biotechs and pharmas either had shutdown weeks or many employees were on vacation. As workers return, the companies hope the investors will, too.
To read Endpoints News become a free subscriber
Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters